Aurobindo's CuraTeQ gains UK approval for biosimilar Dyrupeg

Aurobindo Pharma announced that its wholly-owned step-down subsidiary, CuraTeQ Biologics s.r.o., has received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, a biosimilar version of pegylated filgrastim. The company stated that Lyfius has restarted its production of Penicillin-G with immediate effect as it has been awaiting approval to operate from Andhra Pradesh Pollution Control Board (APPCB). This news closely follows CuraTeQ's receipt of European Commission (EC) approval for Dyrupeg™ in April 2025. Dyrupeg™ is CuraTeQ's third biosimilar to be approved by the MHRA, following Bevqolva™ in December 2024 and Zefylti™ in May 2025. The approval from the MHRA and the EC signifies Aurobindo's continued success in the biosimilar market, expanding its portfolio of approved products and solidifying its presence in key global markets.